Announces cessation of domestic development of MDNT-03. Reassesses resource allocation for the regenerative medicine business and prioritizes management resources toward the cell processing business. Will consider continuing domestic development through external partnerships. No impact on the fiscal year ending September 2026 results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2370","jir_company_name":"MEDINET Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/2370-20261030-02.pdf","jir_short_summary":"Announces cessation of domestic development of MDNT-03. Reassesses resource allocation for the regenerative medicine business and prioritizes management resources toward the cell processing business. Will consider continuing domestic development through external partnerships. No impact on the fiscal year ending September 2026 results.","jir_summary":"### Key Points\nDecided to discontinue domestic development in Japan of MDNT-03 (Stempeucel\u00ae). To improve profitability and strengthen the financial base, the company will reinforce resource allocation to the cell processing business. While regenerative medicine-related development will remain under continuous consideration, the company will explore possibilities to continue domestic development through partnerships with third parties or business transfers. There are no concerns regarding quality or safety.\n\n### Outlook and Impact\nThe cessation of MDNT-03 will have no impact on the fiscal results for the year ending September 2026. Reflection in performance forecasts for the fiscal year ending September 2027 and beyond will be considered. The company will promptly disclose any matters that should be announced. It will continue to strengthen the technological foundation in the cell processing field and pursue future regenerative medicine-related development opportunities.","jir_financial_highlights":"Net Sales: Unknown (Unknown)\nOperating Income: Unknown (Unknown)\nNet Income Attributable to Owners of Parent: Unknown (Unknown)","jir_category":"","jir_hashtags":"#ShareBuybackResponse, #ShareholderReturn, #RegenerativeMedicineDevelopmentPolicy","jir_key_figures":"Decision to discontinue domestic development due to cessation of MDNT-03 development in Japan (figures unknown)\nIncreased allocation of investment to the cell processing business (ratio\/amount unknown)\nNo impact on the fiscal year ending September 2026 results (conclusion)","jir_meta_title":"MEDINET Co., Ltd. Announces Cessation of MDNT-03 Domestic Development | Strengthening Resource Allocation to Cell Processing Business","jir_meta_description":"MEDINET Co., Ltd. announces cessation of domestic development of MDNT-03. The company will reassess investment in the regenerative medicine business and promote strengthening of the cell processing business foundation. It will consider continuing domestic development through third-party partnerships or business transfers. No impact on the fiscal year ending September 2026.","jir_og_title":"Announces Cessation of MDNT-03 Domestic Development | Strengthening Resource Allocation to Cell Processing Business","jir_og_description":"Domestic development of regenerative medicine product MDNT-03 will be discontinued. The company announces strengthening of the financial base and concentration of resources on the cell processing business. It will consider future partnerships or transfers to possibly continue domestic development.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":122814,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-138822","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n